Table 2.
Overall survival analyzed by univariate and multivariate Cox regression models for endometrioid histological subtype
| Variable | Mean (SD) or Frequency (%) | Univariate Hazard Ratio (95% CI, p-value) | Multivariate Hazard Ratio (95% CI, p-value) |
|---|---|---|---|
| Mean Age, years (+/− SD) | 61.9 (11.7) | 1.06 (1.04–1.08, <0.01) | 1.07 (1.04–1.09, <0.01) |
| Mean BMI, kg/m2 (+/−SD) | |||
| <18.5 | 5 (1.0) | Unstable | |
| 18.5–24.9 | 57 (10.9) | 1.00 (ref) | |
| 25–29.9 | 115 (21.9) | 0.80 (0.38–1.66, 0.55) | |
| ≥30 | 348 (66.2) | 0.55 (0.29–1.06, 0.08) | |
| Race | |||
| White | 285 (47.8) | 1.00 | |
| Black | 113 (19.0) | 1.33 (0.76–2.33, 0.32) | |
| Hispanic | 150 (25.2) | 1.21 (0.69–2.12, 0.52) | |
| Other | 45 (8.0) | 0.69 (0.25–1.94, 0.48) | |
| Stage | |||
| I | 489 (84.1) | 1.00 | 1.00 |
| II | 44 (7.6) | 1.66 (0.75–3.67, 0.21) | 1.33 (0.59–2.99, 0.49) |
| III | 36 (6.2) | 2.42 (1.15–5.12, 0.02) | 1.30 (0.56–3.02, 0.55) |
| IV | 12 (2.1) | 7.12 (3.22–15.76, <0.01) | 1.36 (0.47–3.90, 0.57) |
| Grade | |||
| 1 | 380 (64.3) | 1.00 | 1.00 |
| 2 | 137 (23.0) | 2.36 (1.43–3.92, <0.01) | 1.53 (0.87–2.66, 0.14) |
| 3 | 76 (12.7) | 2.63 (1.47–4.72, <0.01) | 1.39 (0.69–2.81, 0.36) |
| Diabetes | |||
| No | 437 (73.7) | 1.00 | 1.00 |
| Yes – Using Metformin | 74 (12.4) | 0.76 (0.35–1.66, 0.49) | 0.79 (0.31–2.00, 0.61) |
| Yes – Not Using Metformin | 82 (13.8) | 0.70 (0.33–1.46, 0.34) | 0.80 (0.36–1.78, 0.58) |
| Hyperlipidemia | |||
| No | 409 (68.9) | 1.00 | 1.00 |
| Yes | 184 (31.1) | 0.61 (0.34–1.09, 0.09) | 0.51 (0.27–0.96, 0.04) |
| Hypertension | |||
| No | 267 (45.0) | 1.00 | |
| Yes | 326 (55.0) | 0.99 (0.63–1.55, 0.97) | |
| Treatment: Radiation | |||
| No | 481 (81.1) | 1.00 | |
| Yes | 112 (18.9) | 1.25 (0.75–2.11, 0.39) | |
| Chemotherapy | |||
| No | 574 (96.8) | 1.00 | 1.00 |
| Yes | 19 (3.2) | 3.33 (1.53–7.25, <0.01) | 7.93 (3.10–20.27, <0.01) |
| Radiation & Chemotherapy | |||
| No | 562 (94.8) | 1.00 | 1.00 |
| Yes | 31 (5.2) | 4.49 (2.42–8.35, <0.01) | 3.82 (1.72–8.46, <0.01) |